Key Stats for Cencora Stock
- This Week Performance: -1.6%
- 52-Week Range: $252.5 to $377.5
- Current Price: $352.7
What Happened?
Cencora (COR), the $352 pharmaceutical distribution giant quietly transforming into a specialty healthcare platform, raised its fiscal 2026 operating income growth guidance to 11.5% to 13.5% after closing its OneOncology acquisition on February 4.
The trigger was a Q1 fiscal 2026 earnings print that delivered 21% U.S. segment operating income growth and $4.08 in adjusted diluted EPS, a 9% increase, prompting an immediate guidance raise that lifted the U.S. segment target to 14% to 16% for the full year.
Driving that outperformance is Cencora’s expanding management services organization strategy, where the company provides back-office and administrative support to specialty physician practices, with OneOncology and Retina Consultants of America now forming a combined oncology and retina platform that carries higher operating margins than core drug distribution.
CFO Jim Cleary stated on the Q1 fiscal 2026 earnings call that “getting into the management services is really the natural evolution of this business,” tying directly to the February 4 close of the OneOncology acquisition that lifted consolidated ownership from 35% to 92%.
With the $3.5 billion MWI Animal Health divestiture announced February 18 sharpening the portfolio toward pharmaceutical-centric growth, long-term guidance raised twice in six months, and a biosimilar and specialty drug pipeline providing durable volume tailwinds through 2030, Cencora’s transition from distributor to specialty platform is now structurally locked in.
Wall Street’s Take on COR Stock
The OneOncology consolidation and MWI divestiture together shift Cencora’s earnings mix toward higher-margin management services, directly accelerating the EPS compounding that the guidance raise already set in motion.
Normalized EPS grew 16.3% in fiscal 2025 to $16.00 and is projected to reach $26.91 by fiscal 2030, a 68% cumulative increase, as OneOncology and RCA drive operating income well above the core distribution baseline, while EBITDA climbs from $4.7 billion to $7.6 billion over the same period on the back of specialty volume growth, biosimilar tailwinds, and a share count held near 195.5 million through the repurchase pause unwinding into resumed buybacks.
Wall Street has turned decisively constructive: 9 buys, 3 outperforms, 3 holds, and 1 underperform among 16 analysts produce a mean price target of $410.00, implying 16.3% upside from the current price of $352.65 as the MSO thesis earns broader acceptance.
The analyst target range runs from $340 to $447, with the low anchored to execution risk from integrating OneOncology and the high requiring the specialty platform to sustain operating income growth at the upper end of the 14% to 16% U.S. segment guidance.
What Does the Valuation Model Say?
The TIKR mid-case prices COR at $461.74 by September 2030, implying 30.9% total return and a 6.1% annualized IRR, driven by a mid-case revenue CAGR of 6.9% and EPS CAGR of 9.0%. The model prices in annual P/E compression of 3.4%, meaning every dollar of return comes from earnings growth, not multiple expansion.
The market still prices Cencora as a thin-margin distributor, yet the MSO platform already delivered 21% U.S. operating income growth in Q1 fiscal 2026.
OneOncology and RCA together now cover the two largest pharmaceutical-centric physician-administered specialties, providing the operating income density the TIKR model’s 9.0% EPS CAGR requires.
Management raised long-term consolidated operating income guidance twice in six months to 10% to 14%, a signal that the MSO earnings contribution is structurally permanent, not cyclical.
The primary risk is specialty drug volume softness: January 2026 IQVIA data already showed weakness, and a sustained deceleration in oncology utilization would directly pressure the U.S. segment operating income growth that anchors the entire model.
The Q2 fiscal 2026 earnings call is the first clean read on OneOncology’s contribution, with U.S. segment operating income growth and the interest expense trajectory as the two numbers to watch.
Should You Invest in Cencora, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up COR stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Cencora, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze COR stock on TIKR for Free →
